Search bioRxiv⌕ Search

Biology subjects

Provencher-Girard, A.

Publications and source records attributed to Provencher-Girard, A..

2 recordsLinked to original sources

Exploration of individual beta cell function over time in vivo: effects of hyperglycemia and glucagon-like peptide-1 receptor (GLP1R) agonism

The coordinated function of beta cells within the pancreatic islet is required for the normal regulation of insulin secretion and is partly controlled by specialized "leader" and highly connected "hub" beta-cell subpopulations. Whether cells within these subpopulations are functionally stable in vivo remains unclear. Here, we establish an approach to monitor Ca2+ dynamics within individual beta cells over time, after engraftment into the anterior eye chamber, where continuous blood perfusion and near normal innervation pertain. Under normoglycemic conditions, islet network dynamics, and the behavior of individual leaders and hubs, remain stable for at least seven days. Hyperglycemia, resulting from high-fat diet feeding or the loss of a host Gck allele, caused engrafted islets to display incomplete and abortive Ca2+ waves and overall connectivity was diminished. Whereas hub cell numbers were lowered profoundly in both disease models, leaders largely persisted. Treatment with the GLP1R agonist Exendin-4 led to a recovery of islet-wide Ca2+ dynamics and the re-emergence of hub cells within minutes, with the effects of the incretin mimetic being more marked than those observed after analogous treatments in vitro. Similar observations were made using 3-dimensional imaging across the whole islet. Our findings thus suggest that incretins may act both directly and indirectly on beta cells in vivo. The approach described may provide broad applicability to the exploration of individual cell function over time in the living animal.

physiology↗

Sex-dependent additive effects of dorzagliatin and incretin on insulin secretion in a novel mouse model of GCK-MODY

Glucokinase (GK) catalyses the key regulatory step in glucose-stimulated insulin secretion. Correspondingly, hetero- and homozygous mutations in human GCK cause maturity-onset diabetes of the young (GCK-MODY) and permanent neonatal diabetes (PNDM), respectively. To explore the possible utility of glucokinase activators (GKA) and of glucagon-like receptor-1 (GLP-1) agonists in these diseases, we have developed a novel hypomorphic Gck allele in mice encoding an aberrantly spliced mRNA deleted for exons 2 and 3. In islets from homozygous knock-in (GckKI/KI) mice, GK immunoreactivity was reduced by >85%, and glucose-stimulated insulin secretion eliminated. Homozygous GckKI/KI mice were smaller than wildtype littermates and displayed frank diabetes (fasting blood glucose >18 mmol/L; HbA1c [~]12%), ketosis and nephropathy. Heterozygous GckKI/+ mice were glucose intolerant (HbA1c [~]5.5%). Abnormal glucose-stimulated Ca2+ dynamics and beta cell-beta cell connectivity in GckKI/+ islets were completely reversed by the recently-developed GKA, dorzagliatin, which was largely inactive in homozygous GckKI/KI mouse islets. The GLP-1 receptor agonist exendin-4 improved glucose tolerance in male GckKI/+ mice, an action potentiated by dorzagliatin, in male but not female mice. Sex-dependent additive effects of these agents were also observed on insulin secretion in vitro. Combined treatment with GKA and incretin may thus be useful in GCK-MODY or GCK-PNDM. Article Highlightsa. Glucokinase deficiency can drive maturity-onset diabetes of the young (GCK-MODY; heterozygotes) and permanent neonatal diabetes (GCK-PNDM; homozygotes) b. We describe a hypomorphic Gck allele where aberrant splicing in islets lowers GK activity to by [~]85%. We use these mice to explore the effects of the glucokinase activator, dorzagliatin, and incretin on insulin secretion c. Whereas heterozygous mutant mice are mildly hyperglycemic, homozygotes have frank diabetes but survive to adulthood. Dorzagliatin potentiates the effects of GLP-1 receptor activation sex-dependently in heterozygotes d. Combined use of these drugs may be useful in some forms of GCK diabetes

physiology↗